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ABSTRACT
Evaluation of photodynamic therapy-induced edema in the rat brain 
using magnetic resonance imaging
by
David Chighvinadze
Dr. Steen Madsen, Examination Committee Chair 
Chair of the Department of Health Physics 
University of Nevada, Las Vegas
Failure of treatment for high-grade gliomas is usually due to local recurrence at the 
site of surgical resection indicating that a more aggressive form of local therapy should 
be used. Photodynamic therapy (PDT) shows promising results in the treatment of 
gliomas as it has been shown to cause significant destruction of tumor cells through 
localized necrosis and/or apoptosis. An unfortunate complication of this therapy is the 
induction of cerebral edema which causes increased intracranial pressure and associated 
morbidity. A potential solution is the administration of steroids to reduce PDT-induced 
edema, associated morbidity, and mortality in treated animals. In the research described 
here, high field strength (3 T) magnetic resonance imaging (MRI) was used for screening 
and detecting the extent and time evolution of PDT-induced edema. Results using inbred 
Fischer 344 rats subjected to PDT showed that this noninvasive imaging technique was 
very useful for studying and evaluating treatment-induced edema, its dependence on the 
PDT light fluence, and the effects of steroids. The data suggest that higher light fluences 
cause greater edema formation and higher mortality, while the addition of postoperative
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steroid treatment reduces the incidence of treatment-induced morbidity and mortality. 
The images also provided information about blood-brain barrier patency, which is 
important in therapeutic regimens involving the delivery of drugs (e.g. chemotherapeutic 
agents) to the brain. PDT appeared to open the BBB for a period of 24-48 hours after 
which it was restored.
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CHAPTER 1 
INTRODUCTION
1.1 Brain tumors
Glioblastoma multiforme (GBM) is the most common and aggressive form of 
primary brain tumor in humans. Most of the malignant tumors originating in the brain are 
gliomas which arise from glial cells. Gliomas account for 40% of all primary brain 
tumors and 78% of malignant tumors (Fig. I). Astrocytomas and glioblastomas account 
for 75% of all gliomas (Fig. 2). Although the most common site of involvement is the 
brain, gliomas can also affect the spinal cord, or any other part of the central nervous 
system (CNS), such as the optic nerves. Gliomas do not metastasize throughout the body, 
unlike most forms of cancer, but cause symptoms by invading the brain; if left untreated, 
the tumor is rapidly lethal.
Gliomas can be categorized according to their grade, which is determined by 
pathologic evaluation of the tumor: Low-grade gliomas are well differentiated, slower 
growing, biologically less aggressive, and portend a better prognosis for the patient. 
High-grade gliomas are undifferentiated or anaplastic, fast growing and can invade 
adjacent tissues, and carry a worse prognosis
There are numerous grading systems, but the most commonly used system is the 
World Health Organization (WHO) grading system for astrocytomas. The WHO system
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assigns astrocytomas a grade from 1 to 4, with 1 being the least aggressive and 4 being 
the most aggressive. Various types of astrocytomas are given corresponding WHO 
grades. WHO Grade 1: e.g. pilocytic astrocytoma; WHO Grade 2: e.g. diffuse 
astrocytoma; WHO Grade 3: e.g. anaplastic (malignant) astrocytoma; WHO Grade 4: 
glioblastoma multiforme (most common glioma in adults).
Low grade (1 and 2) astrocytomas are typically benign, anaplastic astrocytomas 
(grade 3) normally progress from lower grade astrocytomas, and GBM is classified as 
grade 4 due to its high diffuse and invasive properties. GBMs are highly vascular and 
contain necrotic regions with pseudopalisading tumor cells, i.e., hypercellular zones 
surrounding foci of necrosis. The typical histological appearance of gliomas is illustrated 
in Fig. 3.
Symptoms of GBM depend on the area of the brain where the tumor evolves. 
Progressive weakness, speech and/or visual loss occur when "eloquent" brain regions are 
involved and often result in the detection of the tumor at its early stage of development. 
Tumors often become quite large before symptoms appear, causing increased pressure 
and headaches, seizures and in some cases, visual loss from swelling of the optic nerves.
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Figure 1. Distribution of primary brain tumors CBTRUS 1998-2002 (n=25,539). 
(CBTRUS Statistical Report, 2006)
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Figure 2. Distribution of gliomas by histology CBTRUS 1998-2002(n=63,698). 
(CBTRUS Statistical Report, 2006)
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Figure 3. Glioma histology. Grade II individual tumor cells (black structures). In grade 
III anaplastic astrocytoma, cells become more numerous and atypical and are 
characterized by a high mitotic index. Glioblastoma multiforme (black arrows). 
Microvascular hyperplasia is often present as a glomeruloid vascular proliferation (white 
arrow). (Brat et al. 2002)
Once symptoms occur, the diagnosis of GBM is fairly straightforward. The tumor can
be imaged by contrast-enhanced MRI. An open or needle biopsy provides tissue for
microscopic diagnosis. Lower grade astrocytomas respond well to conventional therapies,
while response of GBM to all current treatment modalities is very poor. The primary
treatment for newly diagnosed GBM’s is surgical resection (as enunciated in the National
Comprehensive Cancer Network central nervous system guidelines) (Olson and Ryken
2008). Surgery is usually augmented by conventional fractionated extemal-beam
radiotherapy to the tumor bed (as defined by the Radiation Therapy Oncology Group)
(Harrison et al. 2003), and the administration of chemotherapeutic agents (e.g. the
nitrosoureas such as BCNU, or more recently, temozolomide) (DeAngelis et al. 2001;
Walker et al. 1978 and 1980; Byar et al. 1980; Yung et al. 2000; Sipos et al. 2002). There
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are a number of treatment challenges associated with GBM: 1) location of tumors in 
eloquent areas of the brain preventing complete resection; 2) intrinsic resistance of 
lesions to conventional therapy; 3) limited capacity of the brain to repair itself; 4) the 
spread of malignant cells into the brain parenchyma; 5) the variably disrupted blood- 
brain barrier complicating drug delivery; 6) tumor capillary leakage with resultant 
peritumoral edema and intracranial hypertension; and 7) the neurotoxicity of treatments 
directed at gliomas.
The prognosis is worst for patients with Grade 4 gliomas or GBM. Despite recent 
advances in the therapy of patients with GBM, the median survival is still restricted to 12 
months (Stummer et al. 2008). In recurrent disease, the best possible established second 
line-treatments, apart from surgery, are local chemotherapy with BCNU (Carmustine) 
wafers or temozolomide chemotherapy, which result in an overall survival of less than 8 
months. Novel therapies, such as immunotoxins, administered via convection-enhanced 
delivery, or gene therapy have so far failed phase III evaluations. Therefore, new 
treatment options are desperately needed (Stummer et al. 2008).
Failure of treatment for high-grade gliomas, such as GBM, and its associated high 
mortality, is mostly due to the highly invasive nature of GBM cells, which leads to local 
recurrence at the site of surgical resection, namely in the 2- to 3-cm margin surrounding 
the resection cavity. A potential solution for improving the treatment outcome would be 
to increase the resection area, but in many instances this would be problematic due to 
drastic alterations in brain functionality. The failure of current treatment modalities 
results in poor survival which suggests that a more aggressive form of local therapy, such 
as PDT, could be of benefit.
1.2 Photodynamic therapy
PDT is a local form of therapy used as a treatment for a variety of cancerous and non- 
cancerous conditions. PDT involves administration of a tumor-localizing photosensitizer 
(light-sensitive drug), which can be activated by light of a specific wavelength. A light 
activated photosensitizer transfers energy to molecular oxygen creating singlet oxygen, 
which is a highly reactive and toxic species that rapidly reacts with cellular components 
causing oxidative damage, and ultimately leads to cell death.
Light therapy, both natural and artificial, has been used throughout history for healing 
purposes. Sunlight has been used for medical purposes since the time of the ancient 
Greeks; Hippocrates, the father of modem medicine, prescribed exposure to sunlight for a 
number of illnesses and conditions (e.g. acne). The presence of violet light (405 -  420 
nm) in the solar spectrum has been found to activate a porphyrin (Coproporphyrin III) in 
Propionibacterium acne which damages and ultimately kills the bacteria by releasing 
singlet oxygen.
As the technique advanced, photodynamic therapy became increasingly widespread. 
Currently there are many clinics that use PDT for the treatment of various types of skin, 
lung, esophagus, prostate, eye, and brain tumors. PDT has a number of advantages over 
conventional treatment modalities (surgery, chemotherapy and radiation therapy) 
currently used in oncology. PDT is a highly localized form of treatment, and unlike 
chemotherapy or radiation therapy, which damage normal tissues, PDT causes little or no 
damage to normal tissue. Photosensitizers used for PDT of the brain have a relatively 
high tumor-to-normal brain selectivity (for some drugs this ratio is around 200:1 (Angell- 
Petersen et al. 2006)). By using optical fibers, light can be delivered locally to the tumor.
In biological systems, singlet oxygen generated by photochemical reactions has a very 
short half-life (< 40 ns) and therefore a short range of action (< 20 nm) (Moan et al. 
1991) which minimizes damage to normal tissue. The probability of inducing secondary 
malignancies as a result of PDT is low, as most photosensitizers do not accumulate in cell 
nuclei and therefore PDT generally does not cause DNA damage, mutations and 
carcinogenesis unlike radiation therapy and some chemotherapeutic drugs.
The mechanisms by which photosensitizers selectively accumulate in tumors are 
complex and not fully understood. It is presumably due to abnormal tumor physiology 
which include decreased pH, high vascular permeability due to a leaky vasculature, lack 
of lymphatic drainage, increased number of low-density lipoprotein receptors and 
abnormal stromal composition. (Dougherty et al. 1998).
A number of in vitro and in vivo studies have been conducted to investigate the 
efficacy of PDT as an alternative therapy for high-grade gliomas. In vitro models, 
consisting of monolayer cell cultures, single cell suspensions, and multicellular 
spheroids, have been subjected to a wide variety of PDT treatment regimens. For 
example, PDT efficacy has been studied as a function of numerous parameters including 
photosensitizer dose and type, time of incubation, light dose and dose rate, and light 
fractionation schemes. Several animal glioma models have been developed for the study 
of PDT response in vivo. For example, F98 and BT4C rat glioma models have been used 
in a number of PDT studies since the resultant tumors mimic many of the 
chararacteristics (e.g. infiltrative and invasive behavior) of GBMs (Madsen et al. 2006 
and Madsen et al. 2007). The results indicate that although PDT is capable of producing
significant tumor necrosis, the treatment often results in significant morbidity due to 
increased intracranial pressure caused by PDT-induced edema.
1.3 ALA - PDT
Typically, pre-synthesized sensitizers are used in PDT. The administration of the 
photosensitizer is followed by a delay period (from 30 min. to 7 days depending on the 
drug) to allow selective accumulation in tumor cells. Light irradiation occurs following 
the delay period resulting in either direct tumor cell kill, or indirect toxicity due to the 
destruction of the tumor vasculature. The use of precursor drugs, such as 5- 
aminolevulinic acid (ALA), constitutes a different approach to PDT since the drugs are 
converted to photosensitizers during intracellular biochemical processes.
ALA is a naturally occurring precursor in the biosynthetic pathway for heme 
production, as shown in Fig. 4. The last step in the biosynthetic route involves conversion 
of protoporphyrin IX (PpIX), to heme. PpIX is a porphyrin-based photosensitizer which 
shows great promise in PDT. The compound is a planar aromatic molecule composed of 
four symmetrically arranged pyrrole subunits linked by four methane bridges (Fig. 5) 
(Gibson et al. 1999). Heme biosynthesis starts in the mitochondrion, and under 
physiologic conditions, cellular heme synthesis is regulated in a negative feedback 
control of the enzyme ALA synthase by free heme. ALA synthase then becomes the rate- 
limiting step. When exogenous ALA is added, the control mechanism is bypassed, and 
downstream metabolites are synthesized in excess. Under these conditions, 
ferrochelatase, which catalyzes iron insertion into PpIX, becomes the rate-limiting 
enzyme. Following the addition of exogenous ALA, the low physiologic rate of iron
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insertion by ferrochelatase is unable to compensate for the excess PpIX that is formed. 
This leads to accumulation of PpIX in cells thus making them photosensitive. (Hasan et 
al. 2003; Bemigaud et al. 2008; Gibson et al. 1999) Shortly after administration of ALA 
(approximately four hours) significant amounts of PpIX accumulates in the mitochondria 
and cytosol. The type of cell death associated with ALA-PDT is sensitively dependent on 
the delay interval between administration and light irradiation. At short delay intervals, 
PpIX is largely confined to the mitochondrial membrane and light irradiation during this 
period results in mitochondrial membrane damage, which is associated with an apoptotic 
mode of cell death. At longer delay times, a substantial amount of PpIX may be found in 
the plasma membrane and resultant light irradiation will cause damage to this structure. 
Plasma membrane damage typically results in necrotic cell death.
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Figure 4. The heme biosynthesis pathway. ALA is converted to PpIX, the immediate 
precursor of heme. Heme regulates ALA synthase by negative feedback. Exogenous 
ALA administration bypasses this regulation and causes accumulation of PpIX. (Peng et 
al. 1997)
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Figure 5. Protoporphyrin IX (left), is the immediate preeursor of heme. Insertion of the 
iron atom into the ring structure of protoporphyrin IX generates heme (right).
As shown in Fig. 6, PpIX has a strong absorption peak at 635 nm. Combined with the 
relatively high penetration depth of 635 nm light in tissues, this provides the rationale for 
using this wavelength in ALA-PDT applications. The penetration depth of light is defined 
as the depth at which the light intensity decreases to 37% of its initial value. In normal 
brain and brain tumors, these depths are in the range of 1.5-3.0 mm for 635 nm light. 
(Angell-Petersen et al. 2006)
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Figure 6. PpIX fluorescence excitation spectrum. The penetration depth (ô) of light in 
soft tissue increases with increasing wavelength. The expanded spectrum shows that 
PpIX fluorescence remains unchanged as a function of depth below the tissue surface (0 -  
6 mm). (Peng et al. 1997)
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1.4 Light and oxygen
The mechanism of action of PDT is summarized in Fig. 7. After administration, ALA 
accumulates in the mitochondria of tumor cells and enters the heme cycle. The end result 
of this process is the increased production of PpIX which, when exposed to 635 nm light 
results in its activation to an excited singlet state. Singlet PpIX then undergoes an 
intersystem crossing resulting in triplet PpIX which reacts with ground state triplet 
oxygen resulting in excited singlet oxygen -  a highly reactive toxic species responsible 
for cell death.
'Po
I
I ISC
fluorescence
phosphorescence
I
I
I
I
Figure 7. Jablonski diagram illustrating the interaction between PpIX and oxygen. The 
black arrow indicates the excitation of the photosensitizer to the excited singlet states 
('Pi). ISC - intersystem crossing; ^P, - the sensitizer in the triplet state. (Peng et al. 1997)
A diode laser is the most common light source for PDT, as it is compact, portable,
and has a stable output, producing light of a fixed wavelength needed for photosensitizer
activation. Light is typically delivered through an optical fiber which is directed to the
treatment area. The efficacy of PDT is directly dependent on the production of singlet
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oxygen, therefore tissues must be well oxygenated throughout the treatment. This may 
not always be the ease as certain regions within the tumor may be hypoxic. Furthermore, 
PDT decreases oxygen levels in tissues by consuming oxygen during photodynamie 
reactions, and also by shutting down blood vessels. PDT efficacy may be severely 
compromised in situations where the rate of oxygen consumption exceeds the rate of 
reoxygenation. Potential solutions to this problem include the introduction of dark 
periods during treatment and the use of lower light fluenee rates (Dougherty et al. 1998).
1.5 The blood-brain barrier and cerebral edema
The blood-brain barrier (BBB) is a membrane-like structure composed of tightly 
packed endothelial cells lining the internal walls of the brain capillaries (Fig. 8). Unlike 
peripheral endothelial cells, brain microvascular endothelial cells form a highly selective 
barrier that blocks penetration of most materials into the brain. The function of the BBB 
is to protect the brain and maintain homeostasis by restricting entrance of potentially 
harmful substances and by allowing the entrance of essential nutrients. Large or 
hydrophilic molecules are unable to cross the barrier by themselves without the use of 
specialized carrier-mediated transport mechanisms. The selective nature of the BBB is 
related to its structural components that include: continuous tight junctions, lack of 
fenestration and a low concentration of transport vesicles. Tight junction proteins block 
the paraeellular space and restrict diffusion; they are continuous between adjacent 
endothelial cells lining the brain vasculature. Therefore, to reach the brain interior, 
molecules must pass through endothelial cells by transcytosis. Fenestrations are “holes” 
or “pores” (ranging from 60-350 nm in diameter) in regions of endothelial cytoplasm
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through which materials can diffuse, enter or exit the cell. Endothelial vesicles carry 
solutes across endothelial cells, facilitating transport across blood vessels. Unlike 
peripheral tissues, where endothelial cells have many fenestrations and transport vesicles, 
endothelial cells lining the brain vasculature lack fenestration and have fewer transport 
vesicles. This significantly reduces passive diffusion across the brain endothelium and is 
the reason for the selective permeability of the BBB.
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Figure 8. The blood brain barrier (BBB). Left: brain capillary in cross section showing 
the endothelial cell, tight junctions and the investment of the capillary by astrocytic end 
feet. The impermeability of the BBB mainly relies on the tight junction proteins between 
endothelial cells (Goldstein et al. 1986). Right: electron micrograph showing the 
appearance of tight junctions between neighboring endothelial cells (arrows). (Peters et 
al. 1991.)
Disruption of the BBB permits the entry of plasma fluid into the brain parenchyma,
leading to cerebral edema formation. The word edema comes from the Greek word-
oi ÔT|px% which means “swelling”; it occurs as a result of the breakdown of tight
endothelial junctions, which make up the BBB. Breakdown of this barrier allows
normally excluded intravascular proteins and fluid to penetrate into the cerebral
parenchymal extra-cellular spaces. Once plasma constituents cross the BBB, edema
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spreads quite rapidly and may extend to large areas of the brain. As fluid enters white 
matter it moves extra-cellularly along fiber tracts and can also affect the grey matter. 
Cerebral edema may be either cytotoxic or vasogenic. Cytotoxic edema occurs due to 
changes in cellular metabolism resulting in inadequate functioning of the sodium- 
potassium pump in the glial cell membrane while the BBB remains intact. As is the case 
with other therapeutic interventions, it is assumed that PDT causes vasogenic cerebral 
edema, which occurs as a result of BBB degradation. The formation of cerebral edema is 
quite dangerous as it results in increased intracranial pressure, which impairs vascular 
perfusion and can lead to brain ischemia, herniation and death.
In pre-clinical studies, it has been shown that ALA-PDT is capable of causing 
significant brain tumor necrosis (Madsen et al. 2006). An unfortunate complication of 
this therapy is the induction of cerebral edema, which indicates that ALA-PDT damages 
endothelial cells constituting the BBB. The resultant increase in intracranial pressure 
produces significant morbidity and, in some cases, animals die soon after treatment 
(Madsen et al. 2006)). A potential solution to this problem is the administration of 
steroids, which have the potential to reduce ALA-PDT-induced endothelial cell swelling 
and concomitant re-establishment of the tight junctions responsible for BBB integrity.
1.6 Scope of study
The main purpose of this study is to understand the nature of ALA-PDT-induced 
cerebral edema formation caused by localized disruption of the BBB. Detailed knowledge 
of the parameters affecting edema formation is required in order to optimize ALA-PDT 
for patients with high-grade gliomas. It is hypothesized that: (1) the extent of ALA-PDT-
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induced edema in normal rat brain is dependent on light fluenee -  higher fluences will 
produce larger edema volumes; (2) the extent of edema will peak approximately 1-2 days 
following PDT and thereafter, will diminish rapidly and (3) edema volumes will be 
smaller in animals treated with steroids.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 Animal care
Inbred male Fischer 344 rats (Simonsen Laboratories, Inc, Gilroy, CA) weighing at 
least 300 g were caged in Macrolon 111 cages. The animal holding rooms were maintained 
at constant temperature and humidity on a 12-hour light and dark schedule at an air 
exchange rate of 18 changes per hour. Animal care and protocol were in accordance with 
institutional guidelines. For the surgical procedures, the rats were anaesthetized with 
pentobarbital (25 mg/kg i.p.). Buprenorphin (0.08 mg/kg s.c.) was used as a post­
operative analgesic. The animals received a total of seven doses administered at 12 h 
intervals. All animals were euthanized with Pentobarbital (100 mg/kg i.p.) at the first 
signs of distress.
2.2 ALA-PDT in Fischer rats
Tumor-free rats were used in all studies. The different PDT treatment protocols 
examined are summarized in Table 2.1. Briefly, the extent and time evolution of ALA- 
PDT-induced cerebral edema was evaluated in five groups of animals subjected to 
varying light fluenee and steroid conditions.
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Table 2.1. Experimental groups
Group Description n Purpose
1 Normal brain + 5-ALA-PDT 
(26J, lOmW)
9 Study the extent of edema in normal 
brain in response to 5-ALA-PDT
2 Normal brain + 5-ALA-PDT 
(17J, lOmW)
7 Study the extent of edema in normal 
brain in response to 5-ALA-PDT
3 Normal brain + 5-ALA-PDT 
(9J, lOmW)
4 Study the extent of edema in normal 
brain in response to 5-ALA-PDT
4 Normal brain + 5-ALA-PDT 
(17J, lOmW) + Steroids
4 Determine effects of steroids on 5- 
ALA-PDT induced edema in 
normal brain
5 Normal brain + Light 
(No ALA) Control Group
4 Rule out the possibility of 
hyperthermia- induced edema
Four to five hours prior to light treatment, animals were injected with 125 mg/kg 
ALA intraperitoneally (i.p.). Before treatment, animals were anesthetized, fixed in a 
stereotactic frame (David Kopf Instruments, Tujunga, CA) and the skin covering the skull 
was incised. A 1.0-mm burr hole was then made with an 18-gauge needle. A 400-/<m 
bare flat-end quartz fiber with numerical aperture of 0.22 was introduced directly into the 
brain according to the following coordinates: 3 mm posterior to and 2 mm to the right of 
the bregma with a depth of 5 mm below the dura. Light from a 635 nm diode laser was 
delivered interstitially (10 mW fluenee rate) for a total light fluenee of 26 (group 1), 17 
(group 2) or 9 J (group 3). The corresponding treatment times were 43, 28 and 15 
minutes, respectively. In all cases, moisturizing gel was applied to the animal’s eyes and 
the rat was wrapped in a towel to prevent hypothermia. At the conclusion of treatment, 
the fiber was withdrawn from the brain, and the burr hole was sealed with bone wax. The
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fourth group of animals was subjected to ALA-PDT (26 J, 10 mW) as described above 
and treated with steroids in order to gauge their effects on edema formation. Steroids 
(Solu-Medrol -  1 mg/kg per fraction) were administered in 4 fractions: 1 day prior to 
PDT, on the day of PDT and on 2 consectutive days following PDT. Animals in the 
control group (group 5) were subjected to light treatments (26 J at 10 mW) in the absence 
of photosensitizer to rule out the possibility of hyperthermia-induced edema.
2.3 Magnetic resonance imaging
High-field (3 T) magnetic resonance imaging (MRI) was used for screening and 
detecting the extent and time evolution of PDT-induced edema in the brains of Fischer 
rats. This imaging technique is ideally suited for evaluating the extent and time course of 
edema formation and its noninvasive nature minimizes the number of animals required 
for the studies.
Due to its high water content, edema appears hyperintense (bright) on T2-weighted 
(T2w) images and hypointense (dark) on T1-weighted (Tlw) images. Contrast agents 
were administered to determine BBB disruption. The appearance of contrast 
enhancement on T lw  images following contrast administration was suggestive of BBB 
disruption.
All animals were subjected to the same scanning procedure. Rats were transported to 
the imaging facility via climate controlled private vehicle. Prior to scanning, animals 
were anesthetized with Pentobarbital as previously described. All scanning was 
performed after hours to avoid patient contact. A high field (3 T) MRI (Philips Medical 
Systems, Bothell, WA) scanner was used to acquire all images using the acquisition
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parameters listed in Table 2.2. The anesthetized animal was placed in a specially 
designed Incite immobilization device, which was inserted into the scanner and T lw  and 
T2w images were acquired (Fig. 9).
Table 2.2. MRI acquisition parameters
Acquisition TR
(ms)
TE
(ms)
Flip
angle
FOV
(mm)
Slice
thickens
(mm)
Slice
gap
(mm)
Number
of
slices
Matrix
size
TIW 495 10 85° 40x40 1.5 0 20 80
T2W 3418 80 90° 40x40 1.5 0 20 80
Images were obtained using a flexible surface coil (normally used for scanning the 
human shoulder), which was positioned around the immobilization device. Following the 
initial T1 and T2 imaging sequences, the animal was removed from the scanner and 
injected (i.p.) with a commercial gadolinium-based contrast agent (1.0 ml of 0.5 mmol/ml 
Magnevist: Berlex Laboratories, Wayne, NJ). Approximately 15 min post injection, 
animals were rescanned using a T lw  pulse sequence. The total acquisition time for the 
three scans (Tl-pre, post and T2-pre) was approximately 15 min. Following the image 
procedure, each animal was placed in its cage and transported back to UNLV’s Animal 
Facility. All animals were scanned 4 times, on the day after PDT (dayl), and on days 3, 7 
and 14.
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Figure 9. Imaging setup, a; the high field human MR scanner, b; animal in the 
immobilization device surrounded by a surface coil.
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2.4 Histological preparation
Animals were sacrificed 15-17 days following PDT treatment and their brains 
extraeted. The brains were sectioned along the fiber injeetion traek and fixed by 
immersion in 10 % buffered (pH 7.2) formalin prior to paraffin embedding. Four 
micrometer thick coronal sections were obtained from the original eut surface 
representing the position of the fiber traek and thereafter at 1 ,2  and 3 mm depths. The 
sections were stained with hematoxylin and eosin (H&E) and examined under a light 
microscope by an independent pathologist blinded to the treatment modes.
2.5 Image analysis
Data was analyzed using OsiriXVP software (Fig. 10). Hyperintense signal regions 
(excluding CSF) on the T2w MRI images represent edema. Areas of suspected edema 
content were manually outlined on each slice.
Figure 10. Image analysis. Hyperintense signal regions on the T2w image represent cerebral edema. 
Contouring was performed manually, and edema volume determined using OsiriXVP software.
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Edema volume was calculated according to the following equation:
V=I(S, ■ 0.15) cm'
Where Sj represents the area of the contoured region on slice i as determined by the 
OsiriXVP software, and 0.15 is the slice thickness in cm.
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CHAPTER 3 
RESULTS
3.1 Light fluence
As shown in Figs. 11 and 12, edema formation was sensitively dependent on the PDT 
light fluence: Increased light fluences (9, 17 and 26 J) resulted in a fluence-dependent 
increase in post-operative edema.
Figure 11. T2w MR images illustrating the dose dependence of edema formation. In 
all cases, light was delivered at a fluence rate of 10 mW and images were acquired 1 
day following PDT.
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Figure 12. Edema volume as a function of light fluence 1 day post-PDT treatment.
3.2 Histological analysis
In areas exposed to the highest fluence levels (5-15 /<m from the fiber), no significant 
pathology was observed in coronal sections obtained from animals subjected to a fluence 
of 9 J (Fig. 13c). At higher fluence levels of 17 J, extensive infiltration of lymphocytes 
and macrophages (some loaded with hemosiderin) was apparent (Fig. 13d). Blood vessels 
in these sections showed hyperplastic endothelial cells. At fluence levels of 26 J (data not 
shown), a foe ally extensive area of necrosis with some degeneration of brain parenchyma 
and infiltration of lymphocytes, plasma cells and foamy macrophages (Gitter cells) was 
apparent in the immediate area of the fiber tip. Some of the Gitter cells contained 
hemosiderin, which is suggestive of treatment-induced hemorrhage. Blood vessels in 
these sections also showed hyperplastic endothelium. In contrast, sections taken 1 ,2  or 3 
mm from the fiber track showed no significant pathology for all three of the fluence 
levels tested. Histological sections taken from the brains of light-only control animals 
showed no pathology (data not shown).
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Figure 13. T lw  MRI contrast enhanced images (a, b) showing focal contrast 
enhancement centered around the area of light treatment. PDT treatment to a fluence 
level of 9 (a) and 17 J (b), at a fluence rate of 10 mW was performed 4 h following ALA 
administration (125 mg/kg i.p.). Both scans were performed 1 day post PDT and 15 
minutes following i.p. contrast injection, (c, d) Coronal H&E sections from the brains of 
animals corresponding to a and b taken 15 days post treatment. In the area exposed to the 
highest fluence level (5-15 pim from the fiber) no significant pathology was observed 
following delivery of 9 J (c). At a fluence level of 17 J, extensive infiltration of 
lymphocytes and macrophages (some loaded with hemosiderin) was apparent as denoted 
by the arrow in (d).
3.3 Time evolution of edema
Analyses of T2w images show a marked decrease in edema volume as a function of 
time post-PDT treatment (Figs. 14 - 16). At the highest fluence investigated (26 J), edema 
volume decreased by approximately 50% within a three-day time period post-treatment. 
This time period was found to be a significant prognostic indicator since any animal alive 
on day three was found to be a long-term survivor. Among surviving animals, the edema
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was almost completely resolved by day 14. The results presented in Fig. 16, suggest a 
simple exponential decrease in edema volume with time post- treatment.
Figure 14. Time course of edema development (upper panel: T2w images) and contrast 
enhancement (lower panel: T lw  post-contrast images). Light fluence and fluence rates 
were 26 J and 10 mW, respectively.
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Figure 15. Time course of edema development in animals treated with 26, 17 and 9 L in  
all cases, light was delivered at a fluence rate of 10 mW.
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Figure 16. Decrease in edema volume as a function of time in PDT- treated animals. 
Light fluenee and fluence rates were 17 J and 10 mW, respeetively. The eurve represents 
the best exponential fit to the data.
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3.4 Blood-brain barrier patency
Post-contrast T lw  images are illustrated in Fig. 17. Contrast volumes were measured 
on T lw  images as a function of time post-contrast administration (Fig. 18). The results in 
Fig. 18 show a significant diminution in contrast volume as a function of days post- 
treatment (day 1 -  day 17). The data also show that the rate of increase in contrast 
volume decreases with increasing time post-treatment. Taken together, the results suggest 
that the BBB is closing over the 17-day observation period.
Figure 17. T2w, Tlw-pre and -post contrast enhanced MRI images acquired 1 day 
following PDT. Due to its high water content, edema appears hyperintense (bright) on 
T2w images and hypointense (dark) on T lw  images. Contrast agents were administered 
15 min. prior to scans in order to determine BBB disruption. The appearance of 
enhancement on T lw  images following contrast administration suggests BBB disruption.
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Figure 18. Contrast flow rate across the compromised BBB as a function of time post­
contrast injection and time post-treatment. Light fluenee and fluenee rates were 9 J and 
10 mW, respectively.
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3.5 ALA - PDT + steroid treatment
Steroid treatment resulted in an anticipated reduction of post treatment PDT-induced 
edema formation. Animals treated with steroids, showed immeasurably small or no 
edema on pre-contrast T2 MR images (Fig. 19).
Figure 19. T2w MRI scans of normal rat brains. Left: animal subjected to ALA - PDT 
developed edema. Right: animal treated with ALA - PDT and steroids (Solu-Medrol - 1 
mg/kg per fraction; total of 4 fractions). Both groups of animals received 125 mg/kg 
ALA ip 4 hours prior to light treatment. All animals were treated with 17 J light at a 
fluenee rate of lOmW. Both animals were imaged 1 day following PDT.
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3.6 Controls
As illustrated in Fig. 20, irradiation with laser light alone (26 J, 10 mW) without ALA 
administration provoked no visible damage in the brain tissue. Furthermore, animals did 
not show any abnormal behavior or signs of distress typical for the presence of 
intracranial edema.
Figure 20. T2w MRI scans of rat brains. ALA vs no ALA. a: Light only 26J, b: 9 J, c: 17 
J, d: 26 J. b, c, d, received 125 mg/kg ALA ip 4 hours prior to light treatment (lOmW). 
Images were acquired two days following light treatment.
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CHAPTER 4 
DISCUSSION
Despite ongoing research, the prognosis for patients suffering malignant gliomas 
remains poor with a median survival time of one year for GBM and three years for 
anaplastic astrocytoma (Chang et al. 1998). Following surgery, tumors recur locally in 
more than 80% of cases (Bashir et al. 1988; Wallner et al. 1989). This would suggest that 
a more aggressive form of local therapy, such as PDT, might delay the onset of tumor 
recurrence and hence result in prolonged survival.
A number of rat brain tumor models have been used to investigate the efficacy of 
PDT for the treatment of malignant gliomas. Although several studies have shown that 
PDT is capable of producing significant tumor necrosis, associated edema often results in 
severe morbidity and mortality (Madsen et al. 2006; Ito et al. 2005). The primary 
objective of the present work was to evaluate the extent of ALA-PDT-induced cerebral 
edema in normal rat brain.
The results presented in this work clearly show that ALA-PDT is capable of 
disrupting the BBB resulting in light fluence-dependent cerebral edema. As illustrated in 
Figs. 11,12 and 15, higher light fluences produced greater edema volumes. Of particular 
interest are the results showing that the edema dissipates over time (Fig.s 14, 15, 17) 
suggesting that BBB disruption is reversible and that complete restoration of the BBB is
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possible, although this is clearly a light fluence-dependent phenomenon. Histological 
analyses (Fig. 13) revealed that damage to the BBB occurs following exposure to 
relatively low light fluences: extensive damage was observed at 17 J while no residual 
damage was evident at 9 J suggesting a damage threshold somewhere between these light 
fluences. The substantial edema volumes observed following high fluenee PDT (26 J) 
was attributed to more extensive BBB damage. Not surprisingly, a significant number of 
animals in this group (29 %), died shortly after treatment due to their large edema burden. 
Day 3 of the post-PDT period appeared to be critical: animals that survived past this point 
made a full recovery. This is hardly surprising given the precipitous drop in edema 
volumes between days 1 and 3 (Fig. 15). Interestingly, edema volumes were observed to 
decrease exponentially following PDT (Fig. 16).
BBB dynamics can be inferred from the contrast flow rates presented in Fig. 18. The 
data show that contrast flow rates decreased sharply over the 17 day observation period 
suggesting that the BBB is closing during this interval. The mechanisms by which PDT 
leads to BBB degradation are not clear but likely include direct PDT effects on the 
endothelial cytoskeleton that lead to cell rounding and contraction, probably mediated by 
PDT-induced microtubule depolarization (Sporn and Porter 1992). In addition the 
formation and/or enlargement of endothelial gaps, has been observed in response to PDT 
(Fingar 1996). Additional evidence from fluorescence microscopy studies (Angell- 
Petersen et al. 2006) showing trace amounts of ALA-induced PplX in presumptive 
normal brain support the hypothesis that a direct effect on the capillary endothelial cells 
is the most probable cause for the BBB degradation.
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Low fluenee rate/low fluenee PDT has been demonstrated to enhance the delivery of 
macromolecular drug carriers, in particular liposomally encapsulated doxorubicin (Doxil) 
into murine colon carcinoma tumors growing in the shoulders of mice (Snyder et al. 
2003) These results are in good agreement with other studies which have found a 
significant increase in edema formation, in orthotopic brain tumors, following ALA- 
mediated PDT in a rat brain tumor model indicating a breakdown of the blood-tumor 
barrier (BTB) (Angell-Petersen et al. 2006; Hirschberg et al. 2007). In these cases, the 
BTB was significantly altered by PDT most probably in a similar manner to the one 
proposed here for the BBB by enlarging endothelial gaps. In a recent paper, Hu et al. 
(2007), using a rat C6 glioma model and electron microscopy, showed that PDT changed 
the sub-cellular structure of the BTB with a reduction in the number of cellular 
components in endothelial cells of the capillary blood vessels. They also observed 
stretching of the tight junctions, with an enlargement of the gaps between endothelial 
cells and, in addition, PDT was found to have only a minimal impact on the normal sub- 
cellular structures of the BBB suggesting that the endothelial cells comprising the BBB 
were not permanently damaged by the treatment. These observations are in good 
agreement with the findings of this study, which showed that low fluenee PDT was 
capable of inducing BBB disruption, as evidenced by contrast enhancement on MR 
images, yet no permanent damage was found in histological sections (Fig. 13c). In 
contrast, high fluenee levels are clearly capable of causing significant tissue damage (Fig. 
13d). For example, the tissue damage and immune cell infiltration observed in the region 
in close proximity to the light source are consistent with cerebral ischemia resulting in a 
localized stroke.
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The use of steroids for the management of treatment-induced edema is a common 
strategy employed in the clinic. As shown in Fig. 19, the use of steroids resulted in a 
dramatic decrease in PDT-induced edema and therefore represents a good strategy for 
reducing morbidity and mortality in rats following PDT.
Steroids are powerful immunosuppressive and anti-inflammatory agents which 
mediate BBB dynamics. The exact mechanisms of action are not entirely understood and 
are the subject of intense study. Solu-Medrol (methylprednisolone sodium succinate) -  a 
synthetic glucocorticoid drug was used in this study. Glucocorticosteroids (GCSs) act by 
binding to the intracellular glucocorticoid receptor, resulting in up-regulation or down- 
regulation of specific genes that encode proteins responsible for several cytokines and 
adhesion molecules (Singhal 2006).
The key factors that regulate the permeability of the BBB are vascular endothelial 
growth factor (VEGF), angiopoietin-1 (Ang-1), and angiopoietin-2 (Ang-2) (Kaal et al. 
2004; Lee et al. 2003; Hori et al. 2004; Nag et al. 2005). VEGF is a key regulator of 
angiogenesis and was initially identified as a vascular permeability factor owing to its 
potent property of increasing the permeability of the vascular wall (Senger et al. 1983). 
VEGF disrupts junctions between endothelial cells, leading to increased vascular 
permeability, which results in the breakdown of the BBB (Weis et al. 2005). 
Angiopoietins are ligands for Tie-2, which is a receptor tyrosine kinase expressed on 
endothelial cells and hematopoietic stem cells (Dumont et al. 1992; Iwama et al. 1993). 
Among angiopoietins, the best characterized are Ang-1 and Ang-2 (Yancopoulos et al. 
2002). Ang-1 induces autophosphorylation of Tie-2, while Ang-2 acts as a natural 
antagonist in endothelial cells in the presence of Ang-1 (Maisonpierre et al. 1997). Ang-1
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precludes blood vessels from leaking while Ang-2 destabilizes the vessels. Ang-1 
secreted by brain astrocytes and pericytes contributes to formation of the BBB (Lee et al. 
2003; Hori et al. 2004), whereas Ang-2 directly results in breakdown of the BBB (Nag et 
al. 2005).
It has been suggested that additional nongenomic pathways exist for steroid effects 
occurring at higher concentrations (Singhal 2006). These result from action on 
membrane-bound receptors (specific nongenomic effects) or via physicochemical 
interactions with cellular membranes (nonspecific nongenomic effects). The nongenomic 
effects accelerate the termination of inflammation and may provide the molecular basis 
for the use of high-dose corticosteroids given during pulse therapy. GCSs regulate the 
expression levels of three key factors regulating the BBB: VEGF, Ang-1, and Ang-2 in 
BBB-comprising cells such as human brain astrocytes (HBAs), human brain pericytes 
(HBPs), and human brain microvascular endothelial cells (HBMECs). GCSs up-regulate 
Ang-1 and down-regulate VEGF in HBAs and HBPs, suggesting a novel mechanism for 
steroid-mediated stabilization of the BBB.
The results of the present study demonstrate that low light fluenee ALA-PDT results 
in transient edema suggesting localized opening of the BBB in a reversible manner. It 
thus appears that PDT could offer an alternative to other strategies that have been 
developed to circumvent the BBB including the development of lipid soluble drugs, or 
the use of water-soluble agents with high affinities for natural carriers at the BBB 
(Pardridge et al. 2002; Pardridge et al. 2002). Present techniques for opening the BBB, 
including intra-arterial mannitol infusions, are problematic since they result in 
widespread opening of the BBB allowing entry of cytotoxic drugs and other circulating
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molecules to both the tumor and normal brain in equal quantities (Doolittle et al. 2000). 
For a drug delivery system to be successful, transient and localized targeting of the BBB 
is required. PDT applied through an indwelling balloon applicator, filling the resection 
cavity, could satisfy this requirement (Madsen et al. 2001).
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CHAPTER 5 
CONCLUSIONS
MR imaging proved to be a highly effective and non-invasive method for following 
the development of edema formation and the degree and time course of BBB disruption, 
thus allowing the use of fewer animals. The MR images acquired in this study clearly 
showed that ALA-PDT caused local disruption of the BBB resulting in edema in normal 
rat brain. The extent of PDT-induced edema was dependent on light fluenee: higher 
fluences resulted in increased edema volumes. Only small amounts of edema were 
observed at the smallest fluenee investigated (9 J) whereas extensive edema and 
associated morbidity resulted following exposure to the highest fluenee (26 J). 
Histological studies showed that light fluences as low as 17 J were capable of producing 
long-lasting damage in the rat brain. No permanent damage was observed following 
exposure to 9 J.
Although the exact dynamics of edema formation is somewhat difficult to determine 
from this study, the data suggest that edema volumes peaked approximately 24 h 
following ALA-PDT. Thereafter, edema volumes dissipated rapidly, and in an 
exponential manner, suggesting that BBB disruption was reversible and that eomplete 
restoration of the barrier was possible, at least at the lower light fluenees. This is an 
important observation sinee it suggests that low light fluenee PDT may be used in
38
therapeutic approaches to cause selective and transient opening of the BBB thus 
facilitating the delivery of anti-cancer agents to infiltrating glioma cells normally 
protected by the barrier.
Steroid treatment was found to be very effective at reducing PDT-induced edema and 
represents a sound strategy for reducing morbidity following high light flucncc PDT. The 
aim of future studies will be to optimize steroid treatment regimens, including doses and 
fractionation schemes, in order to minimize PDT-associated edema. Additional studies 
should also be undertaken in order to gain a better understanding of the effects of light 
flucncc on the extent of BBB disruption. For example, electron microscopy is ideally 
suited for determining the size of PDT-induced opening of the barrier. Alternatively, MR 
spectroscopy could be used to assay for the presence of large proteins (exogenous or 
endogenous) normally excluded from the brain by the intact BBB. In this scheme, the 
size of the BBB opening can be inferred from the protein size.
In conclusion, the extent of edema formation in response to ALA-PDT was found to 
be sensitively dependent on the light fluenee. The high light fluenees often used in the 
treatment of animal brain tumors resulted in widespread edema and severe morbidity. In 
contrast, the lowest light fluenee (9 J) investigated in this work produced only a small 
amount of edema and therefore it would appear that low light fluenee ALA-PDT may be 
a reasonable approach for targeted drug delivery to the brain. This has implications for 
the treatment of a variety of CNS diseases including gliomas.
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